PL1654353T3 - Nowotworowe linie komórkowe NM-F9 (DSM ACC2606) i NM-D4 (DSM ACC2605) oraz ich zastosowanie - Google Patents

Nowotworowe linie komórkowe NM-F9 (DSM ACC2606) i NM-D4 (DSM ACC2605) oraz ich zastosowanie

Info

Publication number
PL1654353T3
PL1654353T3 PL04764266T PL04764266T PL1654353T3 PL 1654353 T3 PL1654353 T3 PL 1654353T3 PL 04764266 T PL04764266 T PL 04764266T PL 04764266 T PL04764266 T PL 04764266T PL 1654353 T3 PL1654353 T3 PL 1654353T3
Authority
PL
Poland
Prior art keywords
dsm
threreof
cell lines
tumour cell
acc2605
Prior art date
Application number
PL04764266T
Other languages
English (en)
Inventor
Steffen Goletz
Hans Baumeister
Marion Schlangstedt
Ute SCHÖBER
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of PL1654353T3 publication Critical patent/PL1654353T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL04764266T 2003-08-18 2004-08-18 Nowotworowe linie komórkowe NM-F9 (DSM ACC2606) i NM-D4 (DSM ACC2605) oraz ich zastosowanie PL1654353T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03018576 2003-08-18
PCT/EP2004/009281 WO2005017130A2 (en) 2003-08-18 2004-08-18 Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof
EP04764266.5A EP1654353B1 (en) 2003-08-18 2004-08-18 Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof

Publications (1)

Publication Number Publication Date
PL1654353T3 true PL1654353T3 (pl) 2013-11-29

Family

ID=34178385

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04764266T PL1654353T3 (pl) 2003-08-18 2004-08-18 Nowotworowe linie komórkowe NM-F9 (DSM ACC2606) i NM-D4 (DSM ACC2605) oraz ich zastosowanie

Country Status (9)

Country Link
US (2) US8017388B2 (pl)
EP (1) EP1654353B1 (pl)
CY (1) CY1114643T1 (pl)
DK (1) DK1654353T3 (pl)
ES (1) ES2425475T3 (pl)
PL (1) PL1654353T3 (pl)
PT (1) PT1654353E (pl)
SI (1) SI1654353T1 (pl)
WO (1) WO2005017130A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003260426A1 (en) * 2002-08-16 2004-03-11 Glycotope Gmbh Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
EP1654353B1 (en) 2003-08-18 2013-05-22 Glycotope GmbH Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof
US8609370B2 (en) 2004-02-13 2013-12-17 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
EP1900750A1 (en) * 2006-09-18 2008-03-19 Glycotope Gmbh Fully human high yield production system for improved antibodies
ES2533964T5 (es) 2006-09-10 2024-05-09 Glycotope Gmbh Uso de células humanas de origen leucémico mieloide para expresión de anticuerpos
EP1911766A1 (en) * 2006-10-13 2008-04-16 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
EP1920781B1 (en) 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
TWI604850B (zh) * 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2347769A1 (en) 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
US20130130317A1 (en) 2010-08-02 2013-05-23 Kyowa Hakko Kirin Co., Ltd Method for producing substance
EP2603528B1 (en) 2010-08-10 2016-10-12 Glycotope GmbH Fab-glycosylated antibodies
EP3147355B1 (en) 2010-12-27 2020-07-22 Kyowa Kirin Co., Ltd. Method for preparing aqueous solution containing culture medium and chelating agent
EP2748302B1 (en) 2011-08-22 2018-08-15 Glycotope GmbH Microorganisms carrying a tumor antigen
CN108588030B (zh) * 2018-03-30 2020-07-14 四川迈克生物新材料技术有限公司 抗人IgM单克隆抗体、其杂交瘤细胞株及应用
JP2021524740A (ja) 2018-05-18 2021-09-16 グリコトープ ゲーエムベーハー 抗muc1抗体
EP3875595A4 (en) 2018-11-02 2022-07-13 Kyowa Kirin Co., Ltd. METHOD FOR PREPARING LIQUID CULTURE MEDIUM

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931275A (en) 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
WO1994029469A2 (en) 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
AU723325B2 (en) 1995-06-23 2000-08-24 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
EP0906444A1 (de) 1996-04-19 1999-04-07 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
CA2309766C (en) * 1997-11-20 2008-09-30 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
WO2001023421A2 (en) 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
DE10139428A1 (de) 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
AU2003266236A1 (en) * 2002-07-22 2004-02-09 Nemod Immuntherapie Ag Method for the production of an immunostimulating mucin (muc1)
AU2003260426A1 (en) 2002-08-16 2004-03-11 Glycotope Gmbh Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
EP1654353B1 (en) 2003-08-18 2013-05-22 Glycotope GmbH Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof

Also Published As

Publication number Publication date
EP1654353B1 (en) 2013-05-22
DK1654353T3 (da) 2013-08-26
US20060292129A1 (en) 2006-12-28
SI1654353T1 (sl) 2013-09-30
US8017388B2 (en) 2011-09-13
CY1114643T1 (el) 2016-10-05
WO2005017130A2 (en) 2005-02-24
WO2005017130A3 (en) 2005-06-23
PT1654353E (pt) 2013-08-23
US8283161B2 (en) 2012-10-09
ES2425475T3 (es) 2013-10-15
EP1654353A2 (en) 2006-05-10
US20110319590A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
AP2280A (en) Compositions and methods for increasing telomeraseactivity.
AU2003262747A8 (en) Compounds, compositions, and methods
EP1503993A4 (en) COMPOUNDS, METHODS AND COMPOSITIONS
AU2003236527A8 (en) Compounds, compositions, and methods
AU2003265242A8 (en) Compounds, compositions, and methods
HK1070656A1 (en) Compounds, compositions, and methods
AU2003270015A8 (en) Compounds, compositions, and methods
MXPA03009132A (es) Alquilhidroxamatos triciclicos, su preparacion y su uso como inhibidores de la proliferacion de celulas.
GB0318099D0 (en) Mixing devices,systems and methods
AU2003299612A8 (en) Compounds, compositions and methods
SI1654353T1 (sl) Tumorski celični liniji NM-F9 (DSM ACC2606) in NM-D4 (DSM ACC2605), njihove uporabe
IL167936A0 (en) Compounds, compositions,and methods
EP1705740A4 (en) FUEL FOR FUEL CELL, FUEL CELL AND USE THEREOF
AU2003290507A8 (en) Compounds, compositions and methods
AU2003277079A8 (en) Compounds, compositions, and methods
GB0207205D0 (en) Polyurethane dispersion, manufacture and uses
IL177759A0 (en) Cospeptin, cosmedin and their uses
AU2003267169A8 (en) Compounds, compositions and methods
AU2003300031A8 (en) Compounds, compositions, and methods
AP2006003512A0 (en) Woos treating formulation.
AU2003237209A1 (en) In situ reactor
GB0305089D0 (en) Composition, use and process
EP1660088A4 (en) PYRIDOMORPHINANES, PYRIDAZINOMORPHINANES AND USE THEREOF
GB0229445D0 (en) Process,composition and use
GB0212528D0 (en) Dispersion